Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Instil Bio's basic earnings per share (Basic EPS) for the
three
months ended in Mar. 2026 was $-0.62.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $-7.04.
Instil Bio's EPS (Diluted) for the
three
months ended in Mar. 2026 was $-0.62.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-7.04.
Instil Bio's EPS without NRI for the
three
months ended in Mar. 2026 was $-0.71.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -5.28.
During the past 3 years, the average EPS without NRIGrowth Rate was 39.00% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 11.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 7 years, Instil Bio's highest 3-Year average EPS without NRI Growth Rate was 39.00% per year. The lowest was -141.30% per year. And the median was 4.05% per year.
Instil Bio (NAS:TIL) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Instil Bio EPS (Basic) Related Terms
Instil Bio EPS (Basic) Historical Data
* Premium members only.
The historical data trend for Instil Bio's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Instil Bio's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.04
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Instil Bio (TIL) has a EPS (Basic) of $-7.04 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Instil Bio and its competitors.
Is Instil Bio's EPS (Basic) too high?
Instil Bio's current EPS (Basic) is $-7.04. Overall, Instil Bio has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Instil Bio's EPS (Basic) compare to AURX and MCRB?
Instil Bio's EPS (Basic) of $-7.04 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Instil Bio and its competitors. Instil Bio's current EPS (Basic) is $-7.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instil Bio stock overvalued right now?
Instil Bio (TIL) has a current EPS (Basic) of $-7.04. The current EPS (Basic) is $-7.04. Instil Bio's overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Instil Bio (TIL), the current EPS (Basic) is $-7.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
31GF Score
Get the complete analysis for TIL
EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TIL has been successfully added to your 
